Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary


Home > Formulary : Paediatric > Paediatric Chapters > 7. Obstetrics, gynaecology, and urinary-tract disorders >

BNSSG Paediatric Joint Formulary

7.3 Contraception

Checked: not set yet by Next Review: not set yet

First line drugs Second line drugs Specialist drugs Secondary care drugs

7.3.1 Contraception, combined oestrogen and progesterone

For assessment of venous thromboembolism risk for under16’s follow best practice UK eligibility criteria can be found www.fsrh.org

FSRH guidelines on contraceptive choice for young people

Combined Oestrogen and Progesterone Oral Contraception

Dianette® (co-cyprindiol) is not considered a contraceptive

Type of preparation

Oestrogen content

Progestogen content

Alternative brand

(TLS Blue)

Recommended Formulary brand (TLS Green)

Monophasic low strength

(21-day preparations)

Ethinylestradiol

 20micrograms

 

Desogestrel 

150micrograms

 

Mercilon®

 

Bimizza

Gedarel® 20/150

 

Monophasic standard strength

(21-day preparations)

Ethinylestradiol 

30micrograms

Desogestrel 150micrograms

Marvelon®

Gedarel® 30/150

Levonorgestrel 150micrograms

Microgynon 30®

Ovranette®

Rigevidon®

Levest®

Ethinylestradiol 

35micrograms

Norgestimate

250micrograms

Cilique

Lizinna

N/A

Ethinylestradiol 35 micrograms

Norethisterone 500micrograms

N/A

Brevinor

Ethinylestradiol 35 micrograms

Norethisterone 1000micrograms

N/A

Norimin

Monophasic everyday

 

(28 day preparation)

Ethinylestradiol 30 micrograms

Levonorgestrel 150 micrograms

Microgynon ED

N/A

Combined Contraception – other formulations

Specific indication:

Ethinylestradiol / Norelgestromin patch (Evra®) (TLS Blue)

Qlaira® (estradiol valerate / dienogest) (TLS Amber Specialist Recommended)

  • As an option for patients with premature ovarian insufficiency requiring contraception and HRT cover where standard oral contraceptives are not suitable and patients have completed puberty
  • Non formulary as standard contraception for other patients outside of this cohort

7.3.2 Contraception, oral progesterone-only

Progesterone Only Oral Contraception

Not usually needed in under 18’s but may be considered in cases where oestrogens must be avoided

Type of preparation

Progesterone content

Alternative brand

(TLS Blue)

Recommended Formulary brand

(TLS Green)

Progestogen-only contraceptives

Levonorgestrel 30micrograms

 

Desogestrel 75micrograms

Norgeston®

 

 

Cerazette®

Cerelle®

Or prescribe generically

 

Zelleta

 

 

7.3.3 Emergency Contraception

Emergency Contraception

For advice see Clinical Guideline from the Faculty of Sexual and Reproductive Health

Levonorgestrel 1500 micrograms (Levonelle 1500®) (TLS Green)

Intrauterine device (Copper) (TLS Green)

Specific indication:

Ulipristal (EllaOne®) (TLS Blue)

  • For presenters 72-120 hours after unprotected sexual intercourse, or at the clinician’s discretion (around the time of ovulation)

7.3.4 Contraception, parenteral progestogen-only

Depo-Provera® (Medroxyprogesterone 150mg vial) (TLS Blue)

In adolescents, Depo-Provera® may be used, but only after other methods of contraception have been discussed with the patient and considered unsuitable or unacceptable.

Nexplanon® (Etonogestrel 68mg per rod) (TLS Blue)

 

Intrauterine Progestogen-only Device 

Mirena® (Levonorgestrel intrauterine device) (TLS Blue)

 

7.3.5 Progesterone Receptor Modulators

Ulipristal acetate (Esmya®) (TLS Red) 

 MHRA Alert – indication restricted due to risk of serious liver injury and liver failure. 

  • For the intermittent treatment of moderate to severe symptoms of uterine fibroids, if not eligible for surgical treatment